MedinCell Publishes Its Financial Results for the First Semester Of 2022-2023 (April - September 2022)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
MedinCell (Paris:MEDCL):
Revenue: €7.7 million (+89% compared to the first half of the previous year)
Operating expenses: €19.4 million (+27% compared to the first half of the previous year)
Cash consumption from operations: €10 million
Available cash: €11.7 million in cash and cash equivalent + €2.5 million in non-risky current financial assets in September 30, 2022
Post-closing: expected cash inflows of more than €29 million by the end of the first semester 2023 and revision of the investment plan
Jaime Arango, MedinCell's Chief Financial Officer stated: "We have a good cash visibility through at least the end of the first quarter of 2024. Our pipeline continues to advance with a first product close to commercialization and two others in Phase 3. Several of our internal programs should reach clinical stage next year and and two new ones have started in major indications. In parallel, our financial strategy and investment plan have evolved in light of the global financial environment."
Development of the product portfolio based on BEPO technology®
mdc-IRM (schizophrenia): Commercialization as UZEDY™ expected in the first half of 2023 by Teva in the U.S., subject to FDA approval.
- Teva receives a Complete Response Letter (CRL) from the US FDA in April 2022
- Resubmission of the marketing application announced on November 3, 2022 by Teva, which expects a six-month review period.
mdc-TJK (schizophrenia): decision by Teva to move to clinical Phase 3 in the U.S. announced in August 2022.
mdc-CWM / F14 (post-operative pain): launch of a Phase 3 clinical study in the U.S. by MedinCell's partner AIC. The first patient was enrolled on November 18, 2022 (post-closing).
Advancement of preclinical activities for three programs that should be ready for the start of clinical trials in 2023: mdc-GRT (immunosuppressor/transplantation), mdc-WWM (contraception) with the support of the Bill & Melinda Gates Foundation, and mdc-STM (malaria) with the support of Unitaid.
Substantial milestones planned in 2023 for mdc-KPT (animal health) and mdc-TTG (Covid-19) could enable to engage partners to pursue their development.
Launch of formulation activities for two new internal products (at this stage, the details of these programs are confidential).
Several collaborations with pharmaceutical partners are currently in technical feasibility studies, a necessary step before the launch of formulation activities.
In addition to these activities, MedinCell continues to work on expanding its internal programs portfolio.
Details of the portfolio of products in regulatory development as of December 6, 2022
HUMAN HEALTH
Program awaiting marketing authorization
mdc-IRM Treatment of schizophrenia Partner: Teva Active ingredient: Risperidone |
The US marketing application was filed in June 2021 by Teva and accepted for review by the US Food and Drug Administration (FDA).
|
Programs at the clinical stage
mdc-TJK Treatment of schizophrenia Partner: Teva Active ingredient: Olanzapine |
In August 2022, Teva informed MedinCell of its decision to initiate a Phase 3 clinical trial for mdc-TJK. |
mdc-CWM Postoperative pain and inflammation Partner: Arthristis Innovation Corporation Active ingredient: Celecoxib |
Post closing: A Phase 3 clinical trial conducted in the U.S. and funded by AIC began in November 2022.
|
Next potential candidates for clinical development
mdc-GRT Organ transplantation MedinCell Program Active ingredient: Tacrolimus |
Regulatory preclinical activities are underway.
|
mdc-TTG Covid-19 MedinCell Program Active ingredient: Ivermectin |
Results of the SAIVE Phase 2 clinical trial, which aims to demonstrate the prophylactic efficacy of regular, daily, oral ivermectin, are expected in early 2023.
|
mdc-WWM Contraception Partner: Bill & Melinda Gates Foundation Active ingredient: Progestin (not MPA) |
Regulatory preclinical activities are underway.
|
mdc-ANG Schizophrenia Partner: Teva Active ingredient: Confidential |
The eventual start of clinical activities will depend on the conclusions of the ongoing analysis of preclinical data and the decisions of our partner Teva. |
mdc-IRM Neuroscience Partner: Teva Active ingredient: Risperidone |
Teva initiated preclinical regulatory activities in May 2022 to seek approval for mdc-IRM in an additional neurology indication. |
mdc-STM Malaria Partner: Unitaid Active ingredient: Ivermectin |
Following the selection of a candidate formulation in June 2021, preclinical activities have begun with the objective of starting regulatory toxicology studies in 2023. |
ANIMAL HEALTH
mdc-KPT Pain MedinCell Program Active ingredient: Confidential
|
The company believes that during the first half of 2023 it will have all the necessary data to engage the best partner to continue the development of this important asset for animal health.
|
Selected financial information for the first half of 2022*
Consolidated key data - IFRS (In thousands of €) |
30/09/2022 |
30/09/2021 |
6 months |
6 months |
|
PROFIT AND LOSS ACCOUNT |
|
|
Revenues from sales |
6 027 |
1 602 |
Other income from ordinary activities |
1 682 |
2 477 |
Current operating income |
(11 652) |
(11 215) |
Operating income |
(11 657) |
(11 214) |
Financial result |
(2 090) |
(544) |
Net income |
(13 747) |
(11 758) |
CASH FLOW |
|
|
Net cash linked to operating activities |
(9 962) |
(11 293) |
Net cash linked to investing activities |
(230) |
463 |
Net cash linked to financing activities |
(2 700) |
(1 871) |
BALANCE SHEET |
30/09/2022 |
31/03/2022 |
Consolidated shareholders' equity |
(26 069) |
(13 371) |
Total non-current liabilities |
41 291 |
19 433 |
Total current liabilities |
17 554 |
38 241 |
Total non-current assets |
11 651 |
10 229 |
Of which financial assets and other non-current assets |
3 227 |
1 519 |
Total current assets |
21 125 |
34 074 |
Of which cash and cash equivalents |
11 727 |
24 617 |
FINANCIAL DEBT |
|
|
Financial debt, non-current portion |
38 224 |
16 249 |
Financial debt, current portion |
6 863 |
27 764 |
GROSS FINANCIAL DEBT |
45 087 |
44 014 |
Cash and cash equivalents |
11 727 |
24 617 |
Capitalization contract ** |
2 542 |
2 560 |
NET FINANCIAL DEBT |
30 818 |
16 837 |
* The auditors’ report will be finalized and issued in the coming days
** The Group has sums tied up in a capitalization contract and euro funds given as security for a bank loan of €7 million, the balance of which to be repaid amounts to €0.1 million at September 30, 2022.
Financial visibility assured at least until the first quarter of 2024
As of September 30, 2022, MedinCell had €11.7 million of cash and €2.5 million of non-risky current financial assets, compared to €24.6 million of cash and €2.5 million of non-risky financial assets as of March 31, 2022.
Cash flow from operations for the first half of the year reflects the increased investment required to expand and advance the Company's product portfolio.
In November 2022, the Company definitively signed an agreement for an additional €40 million in financing with the European Investment Bank of which around €23 million will be used to repay existing funding.
The estimated cash visibility includes more than €29 million of post-closing cash cashing:
- US$ 4 million from the Bill & Melinda Gates Foundation received in November 2022 as part of the grant awarded in 2019 for the mdc-WWM project
- €7 million net from the first two tranches of the new loan signed with the European Investment Bank, which can be cashed in immediately
- An additional €10 million from the same loan, available upon approval of mdc-IRM, expected in the first half of 2023
- €4.2 million of Research Tax Credit expected in Q1 2023
- Anticipation of a US$ 4 million milestone payment and commercial launch of mdc-IRM in the first half of 2023 following the announcement of the new drug application by Teva on November 3, 2022
The estimated financial visibility does not include revenues that could be derived from:
- Licensing of our internal products
- Licensing of our technologies
- Transfer of licenses after feasibility studies in progress or to come
- New agreements with our existing partners
Consolidated statement of cash flows*
|
(In thousands of €) |
30/09/2022
|
30/09/2021
|
|
A |
NET CASH LINKED TO OPERATING ACTIVITIES |
(9 962) |
(11 293) |
|
B |
NET CASH LINKED TO INVESTING ACTIVITIES |
(230) |
463 |
|
C |
NET CASH LINKED TO FINANCING ACTIVITIES |
(2 700) |
(1 871) |
|
|
NET CHANGE IN CASH POSITION |
(12 889) |
(12 703) |
|
|
Cash and cash equivalents - opening balance |
24 617 |
47 095 |
|
|
Cash and cash equivalents - closing balance |
11 727 |
34 392 |
* The auditors’ report will be finalized and issued in the coming days
A- Net cash generated from operating activities
Company's cash burn was €10 million during the first six months of the year. Revenue for the period is mainly composed of a € 2.9 million milestone payment from Teva following the decision to start Phase 3 activities for mdc‑TJK.
B- Net cash generated from investing activities
The negative flow is mainly due to the company's tangible and intangible investments (€0,4 million) during the period. In the previous year, a positive revaluation of investment securities had created a positive variation in this flow.
C- Net cash generated from financing activities
This negative cash flow of €2.3 million is mainly due to the repayment of the existing debt. On April 1st, 2022 MedinCell received the balance of the conditional advance of €0.6 million from the Occitanie region under a Growth Contract.
Income Statement
Revenue from ordinary activities: €7.7 million
Revenues for the first semester of the 2022-2023 financial year, up 89% compared to the previous period, were generated by (i) the payment of a milestone of € 2.9 million by Teva for the transition to Phase 3 of the mdc-TJK program, and services rendered in connection with (ii) the collaboration with the Bill & Melinda Gates Foundation (development of an injectable female contraceptive active for 6 months), (iii) the collaboration with the international agency Unitaid (project aimed at combating malaria transmission) and (iv) new collaborations.
The company also points out that the first revenues linked to product sales should be royalties from the marketing of the first mdc-IRM product developed with Teva. Until then, due to the product development cycle and depending on the financial parameters set up within the framework of partnerships (which may or may not include certain elements such as invoicing for formulation services, milestone payments, royalties, cost sharing, profit sharing, etc.), its revenues may vary significantly from one period to another.
The company benefits from the Research Tax Credit for its research and development (R&D) activities, which is recorded under "Other income from ordinary activities". It’s down 32% from last year due to the progress of the programs, as clinical CRO expenses are not included in the scope of expenses eligible for the Research Tax Credit.
Current operating expenses in line with the development of the Company's portfolio: €19.4 million
Operating expenses increased by 27% compared to the same period of the previous year in line with the resumption of activities and the progress of the various programs.
More than 76% of expenses were for R&D with cost increased by 32% in the first semester. In line with forecasts and the company's strategy of expanding its product portfolio, R&D expenses were mainly dedicated to non-clinical and clinical CRO services, and CMO services to advance programs in formulation research or in preclinical studies to prepare the next steps.
Marketing and sales expenses increased by 19% compared to the same period of the previous year, returning to normal levels after two years of restrictions. The Business and Development teams have also been strengthened.
Overheads increased slightly by 11% over the period, mainly due to personnel costs, travel and relocation costs following the lifting of health restrictions, as well as rent and related costs in view of the move to new premises in January 2022.
Net financial income: €(2.1) million
The increase in financial expenses is mainly due to the re-estimation of the variable remuneration of the EIB loan of €1.6 million, as well as the effects of the new amendment signed on June 1, 2022. These expenses were partially offset by foreign exchange gains over the period due to the favorable evolution of the euro/US dollar rate.
Consolidated income statement*
(In thousands of €) |
30/09/2022
|
30/09/2021
|
Var
|
Var % (%) |
|
Revenue from development services |
2 702 |
1 602 |
1 100 |
69% |
|
Milestones |
2 902 |
- |
2 902 |
0% |
|
Royalties |
423 |
- |
423 |
0% |
|
Revenues from sales |
6 027 |
1 602 |
4 425 |
276% |
|
Research tax credit |
1 682 |
2 483 |
(801) |
(32%) |
|
Other income |
- |
(6) |
6 |
NA |
|
Other income from ordinary activities |
1 682 |
2 477 |
(795) |
(35%) |
|
A- Revenue |
7 709 |
4 080 |
3 629 |
89% |
|
Cost of goods and services sold |
- |
- |
- |
0% |
|
Research and development costs |
(14 732) |
(11 187) |
(3 545) |
32% |
|
Marketing and sales costs |
(1 308) |
(1 106) |
(202) |
18% |
|
General and administrative costs |
(3 321) |
(3 003) |
(318) |
11% |
|
B- Total operating expenses |
(19 361) |
(15 296) |
(4 065) |
27% |
|
Current operating income |
(11 652) |
(11 215) |
(437) |
4% |
|
Other non-current operating expenses |
(62) |
(1) |
(61) |
n.a. |
|
Other non-current operating income |
57 |
2 |
55 |
n.a. |
|
Operating income |
(11 657) |
(11 214) |
(443) |
4% |
|
Financial interest income |
11 |
56 |
(45) |
-80% |
|
Cost of gross financial debt |
(3 479) |
(872) |
(2 607) |
299% |
|
Other financial expenses |
(12) |
(5) |
(7) |
140% |
|
Other financial income |
1 380 |
277 |
1 103 |
398% |
|
Financial income |
(2 090) |
(544) |
(1 546) |
284% |
|
Income from companies accounted for by the equity method |
- |
- |
- |
0% |
|
Income before taxes |
(13 747) |
(11 758) |
(1 989) |
17% |
|
Tax income/ (expense) |
- |
- |
- |
0% |
|
Net income |
(13 747) |
(11 758) |
(1 989) |
17% |
|
- Attributable to MedinCell shareholders |
(13 747) |
(11 758) |
(1 989) |
|
|
- Attributable to non-controlling interests |
- |
- |
|
|
|
Earnings per share (in €) |
(0,55) |
(0,47) |
|
|
|
Diluted earnings per share (in €) |
(0,55) |
(0,47) |
|
|
|
* The auditors’ report will be finalized and issued in the coming days
Summary of the balance sheet*
(In thousands of €) |
30/09/2022 |
31/03/2022 |
Total non-current assets |
11 651 |
10 229 |
Total current assets |
21 125 |
34 074 |
TOTAL ASSETS |
32 776 |
44 303 |
Consolidated shareholders' equity |
(26 069) |
(13 371) |
Total non-current liabilities |
41 289 |
19 433 |
Total current liabilities |
17 554 |
38 241 |
TOTAL LIABILITIES |
32 776 |
44 303 |
* The auditors’ report will be finalized and issued in the coming days
Other highlights of the first half
In August 2022, MedinCell published its annual CSR report which details the different pillars of its ESG policy, its implementation through concrete and clearly defined objectives, and the evolution of the company's non-financial data.
In May 2022, Dr. Richard Malamut, a pharmaceutical development specialist in the United States, joined MedinCell as Medical Director in charge of clinical development and regulatory affairs. He had notably overseen the initial clinical strategy for mdc-IRM at Teva (2013-2016). He was previously Chairman of MedinCell's Medical Board and an observer on the Company's Supervisory Board. Joël Richard resigned from the Executive Board in October 2022 and will definitely leave the company in January 2023.
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. MedinCell collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options. Based in Montpellier, MedinCell currently employs more than 150 people representing over 30 different nationalities.
*This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.
These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", “expect”, "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", “potential”, "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these
risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are encouraged to inquire about, and required to comply with, these restrictions.
Contacts
MedinCell
David Heuzé
Head of Communications
david.heuze@medincell.com
+33 (0)6 83 25 21 86
NewCap
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94
NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94
Editor Details
-
Company:
- Businesswire
